EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, has launched ExoXpert, a contract development and manufacturing organization (CDMO) specializing in exosomes.
 
ExoXpert offers an MSC-based exosome manufacturing platform used in European clinical trials and is a wholly owned subsidiary of EXO Biologics.

Serving Demand from Exosome Developers with the ExoPulse Platform

During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing platform designed for GMP production of exosomes. In July 2023 the European Medicines Agency (EMA) authorized the EVENEW study, a Phase 1/2 European clinical trial using EXOB-001. This is EXO Biologics’ lead MSC-based exosome candidate for prevention of Bronchopulmonary Dysplasia (BPD) in preterm newborns.
 
ExoXpert will operate the ExoPulse platform to serve demand from exosome developers for R&D-grade exosome vials as well as GMP manufacturing capabilities.
 
“Currently there is a lack of exosome production, manufacturing specialists and facilities to supply exosomes for both R&D and clinical trials,” said Romain de Rauville, Chief Business Officer, EXO Biologics. “ExoXpert has been launched using our expertise in the development of exosome-based therapeutics to offer GMP-compliant specialist exosome manufacturing capabilities to the market. This will make a significant contribution to the industry’s efforts to develop exosome-based products.”
 
ExoXpert has an exosome manufacturing plant with Grade A/B and C clean rooms, highly specialist staff and management. ExoXpert will utilize the ExoPulse manufacturing platform, which comprises upstream, downstream, analytical and quality-controlled processes at an industrial scale. This will provide affordable manufacturing solutions to exosome developers.
 
ExoXpert is based in the Legiapark biotech campus in Liege, Belgium. The facility is close to European and U.S. connections via Brussels airport.
 
“Challenges around producing and characterizing exosomes remain a significant barrier to the development of exosome-based therapeutics and their delivery to patients. In addition, navigating the regulatory pathways to their production is a major hinderance across the market,” said Hugues Wallemacq, CEO, EXO Biologics. “EXO Biologics has now developed a regulatory-compliant GMP manufacturing platform and facility that provides a solution to biotech companies developing exosome-based therapeutics.”
 
Wallemaxq added, “ExoXpert is already supporting the development of products for two biotech companies and is at the center of ExoFasttrack, a major Biowin project, to create an industrial exosome ecosystem. EXO Biologics has launched ExoXpert to be a major division of the Company with the aim of contributing to the global development of exosomes.”